Feature-fusion model prioritizes antibacterial Ugi products
LSCNN ranked a combinatorial Ugi library after model development on focused activity data. The paper reports six active products among ten selected combinations against MRSA; purified H4–H6 had MIC and MBC of 12 μM. Different screening phases and cutoffs mean these figures are not a randomized general hit-rate comparison.
Technology: LSCNN feature-fusion neural network
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Primary article reports 6/10 selected combinations active against MRSA and purified H4–H6 MIC/MBC results.
- Still unknown: Prior chemical-structure overlap, full independent replication, and clinical efficacy are not established.
- AI role: Model ranks products from combinatorial Ugi space for synthesis and testing.
Evidence sources: https://pubs.rsc.org/en/content/articlepdf/2024/sc/d3sc06441g · https://pmc.ncbi.nlm.nih.gov/articles/PMC11041243/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: Primary source checked for identity, date, model role and bounded reported result..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.